symcare 5 mg tabletki powlekane
symphar sp. z o.o. - solifenacini succinas - tabletki powlekane - 5 mg
symcare 10 mg tabletki powlekane
symphar sp. z o.o. - solifenacini succinas - tabletki powlekane - 10 mg
kimoks 400 mg tabletki powlekane
alkaloid - int d.o.o. - moxifloxacinum - tabletki powlekane - 400 mg
bocouture 100 j. toksyny botulinowej typu a (150 kd)/ fiolkę proszek do sporządzania roztworu do wstrzykiwań
merz pharmaceuticals gmbh - toksyna botulinowa typu a (150 kd) wolna od białek kompleksujących - proszek do sporządzania roztworu do wstrzykiwań - 100 j. toksyny botulinowej typu a (150 kd)/ fiolkę
alprazolam aurovitas 1 mg tabletki
aurovitas pharma polska sp. z o.o. - alprazolamum - tabletki - 1 mg
abiazyt 500 mg tabletki powlekane
artespharm sp. z o.o. - azithromycinum - tabletki powlekane - 500 mg
adablok 5 mg tabletki powlekane
adamed pharma s.a. - solifenacini succinas - tabletki powlekane - 5 mg
adablok 10 mg tabletki powlekane
adamed pharma s.a. - solifenacini succinas - tabletki powlekane - 10 mg
nifelox 5 mg tabletki powlekane
synoptis pharma sp. z o.o. - solifenacini succinas - tabletki powlekane - 5 mg
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.